X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EDP-323 is an oral, L-protein inhibitor in development for the treatment of respiratory syncytial virus. It has shown sub-nanomolar potency against several RSV-A and RSV-B strains in vitro.
Lead Product(s): EDP-323
Therapeutic Area: Infections and Infectious Diseases Product Name: EDP-323
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
EDP-235 is an oral, 3CL protease inhibitor, which is being investigated in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.
Lead Product(s): EDP-235
Therapeutic Area: Infections and Infectious Diseases Product Name: EDP-235
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2023
Details:
EDP-235 is a 3CL protease inhibitor, having the ability to suppress viral replication and transmission. It is in development as an once-daily, oral formulation, treatment for COVID-19.
Lead Product(s): EDP-235
Therapeutic Area: Infections and Infectious Diseases Product Name: EDP-235
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2023
Details:
Through the divestment, Enanta will sale a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir) to OMERS Life Sciences. The net sale proceeds will be used to fund the continuing clinical development of virology pipeline.
Lead Product(s): Glecaprevir,Pibrentasvir
Therapeutic Area: Infections and Infectious Diseases Product Name: Mavyret
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: OMERS Life Sciences
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Divestment April 25, 2023
Details:
EDP-323 is an oral, L-protein inhibitor in development for the treatment of respiratory syncytial virus. It has shown sub-nanomolar potency against several RSV-A and RSV-B strains in vitro.
Lead Product(s): EDP-323
Therapeutic Area: Infections and Infectious Diseases Product Name: EDP-323
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2023
Details:
EDP-235 is a 3CL protease inhibitor, having the ability to suppress viral replication and transmission. It is in development as an oral formulation, once-daily, treatment for COVID-19.
Lead Product(s): EDP-235
Therapeutic Area: Infections and Infectious Diseases Product Name: EDP-235
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
Preclinical data show that EDP-235 potently blocks the replication of SARS-CoV-2 in multiple cellular models. Preclinical studies also show that EDP-235 has favorable distribution into lung cells as well as other key target tissues.
Lead Product(s): EDP-235
Therapeutic Area: Infections and Infectious Diseases Product Name: EDP-235
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
EDP-235 achieved excellent penetration into monocytes and macrophages, including lung AM. EDP-235 has the potential to eliminate viral replication of SARS-CoV-2 in these critical immune cells, thus mitigating macrophage-mediated cytokine storm in high-risk COVID-19 patients.
Lead Product(s): EDP-235,Midazolam,Rosuvastatin
Therapeutic Area: Infections and Infectious Diseases Product Name: EDP-235
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
EDP-323 is a potent inhibitor of respiratory syncytial virus (RSV) replication and has the potential to be a best-in-class, broad spectrum, once daily, oral antiviral treatment for respiratory syncytial virus (RSV).
Lead Product(s): EDP-323
Therapeutic Area: Infections and Infectious Diseases Product Name: EDP-323
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
EDP-938 is a nanomolar inhibitor of both RSV-A and RSV-B activity, in treatment of adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications.
Lead Product(s): EDP-938
Therapeutic Area: Infections and Infectious Diseases Product Name: EDP-938
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
